苯丙胺与卡西酮类物质与急性冠脉综合征的关联:一项系统综述
该系统综述检索了PubMed、Embase、Cochrane图书馆、PsycInfo和Web of Science自建库至2022年8月31日的文献,纳入描述成人使用苯丙胺或卡西酮后发生急性冠脉综合征的原始英文或荷兰语文章。共识别11,605篇文章,56篇符合纳入标准,涉及160例苯丙胺相关急性冠脉综合征患者和4234例卡哈特咀嚼相关患者。在已知急性冠脉综合征类型的患者中,ST段抬高型心肌梗死53例(75%),非ST段抬高型心肌梗死18例(25%);ST段抬高型心肌梗死患者中36%诊断为显著冠脉狭窄或血栓。作者结论认为苯丙胺类兴奋剂和卡西酮类物质与急性冠脉综合征发生相关,卡哈特咀嚼似乎是急性冠脉综合征的危险因素,但证据有限、质量低且报告病例数少,需进一步前瞻性研究。
要点
- 系统综述纳入56篇文献,报告160例苯丙胺类相关急性冠脉综合征患者,涉及苯丙胺48例、甲基苯丙胺98例、3,4-亚甲二氧基甲基苯丙胺11例、芬乙茶碱2例、4-氟苯丙胺1例。
- 卡哈特咀嚼相关急性冠脉综合征报告4234例,合成卡西酮类相关报告3例(未定义卡西酮1例、4-甲基甲卡西酮1例、α-吡咯烷基苯戊酮1例)。
- 在已知急性冠脉综合征类型的157例患者中,ST段抬高型心肌梗死53例(75%),非ST段抬高型心肌梗死18例(25%);ST段抬高型心肌梗死患者中36%诊断为显著冠脉狭窄或血栓。
- 卡哈特相关急性冠脉综合征死亡率高于非卡哈特相关急性冠脉综合征,卡哈特组更多为男性和年龄较大患者且心血管危险因素较少。
- 苯丙胺、甲基苯丙胺和3,4-亚甲二氧基甲基苯丙胺相关ST段抬高型心肌梗死和非ST段抬高型心肌梗死死亡率分别为14%和7%。
适用人群与场景
- 成人患者,使用苯丙胺或卡西酮后发生急性冠脉综合征;纳入原始英文或荷兰语文章。
研究设计与关键结果
- 研究类型:系统综述,遵循PRISMA指南;检索PubMed、Embase、Cochrane图书馆、PsycInfo和Web of Science自建库至2022年8月31日,共识别11,605篇文章,56篇符合纳入标准。
- 苯丙胺类相关急性冠脉综合征共160例,涉及五种类型:苯丙胺(n=48)、甲基苯丙胺(n=98)、3,4-亚甲二氧基甲基苯丙胺(n=11)、芬乙茶碱(n=2)、4-氟苯丙胺(n=1)。
- 卡哈特咀嚼相关急性冠脉综合征报告4234例;合成卡西酮类相关报告3例:未定义卡西酮(n=1)、4-甲基甲卡西酮(n=1)、α-吡咯烷基苯戊酮(n=1)。
- 在已知急性冠脉综合征类型的157例患者中,ST段抬高型心肌梗死53例(75%),非ST段抬高型心肌梗死18例(25%);ST段抬高型心肌梗死患者中36%诊断为显著冠脉狭窄或血栓。
- 卡哈特相关急性冠脉综合征死亡率高于非卡哈特相关急性冠脉综合征,卡哈特组更多为男性和年龄较大患者且心血管危险因素较少。
- 苯丙胺、甲基苯丙胺和3,4-亚甲二氧基甲基苯丙胺相关ST段抬高型心肌梗死和非ST段抬高型心肌梗死死亡率分别为14%和7%。
- 急性冠脉综合征危险因素报告不频繁,风险分层评分未报告。
证据类型、等级与局限
- 证据类型:系统综述;作者指出证据有限、质量低且报告病例数少。
- 局限:证据有限、质量低、报告病例数少;需进一步前瞻性研究。
对床旁实践的改变
- 作者认为,有证据表明苯丙胺类兴奋剂和卡西酮类物质与急性冠脉综合征发生相关;卡哈特咀嚼似乎是急性冠脉综合征的危险因素。
- 作者认为,苯丙胺、甲基苯丙胺、3,4-亚甲二氧基甲基苯丙胺、芬乙茶碱、4-氟苯丙胺和合成卡西酮类也有与急性冠脉综合征相关的报告,但证据有限、质量低且报告病例数少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It is well known that cocaine increases the risk of acute coronary syndrome. However, it is uncertain if the use of other stimulants, such as amfetamines and cathinones, is also related to acute coronary syndrome.
OBJECTIVES: To identify all reported cases of acute coronary syndrome related to the use of amfetamines and cathinones, the type of acute coronary syndrome, the atherothrombotic aetiology, and the mortality rate.
METHODS: A systematic literature search in PubMed, Embase database, Cochrane library, PsycInfo and Web of Science was performed from inception until 31 August 2022. All original articles in English or Dutch describing adult patients with acute coronary syndrome after the use of amfetamines or cathinones were included. The main outcome was the occurrence of acute coronary syndrome associated with amfetamine-type stimulants or cathinones. Data were collected and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
RESULTS: A total of 11,605 articles were identified, 56 of which met the inclusion criteria. A total of 160 patients presented with acute coronary syndrome after five different types of amfetamines, namely, amfetamine (n = 48), metamfetamine (n = 98), 3,4-methylenedioxymetamfetamine (n = 11), fenethylline (n = 2), and 4-fluoroamfetamine (n = 1). Khat chewing was associated with acute coronary syndrome (n = 4234), as were three different types of synthetic cathinones, namely, non-defined cathinones (n = 1), 4-methylmethcathinone (n = 1), and α-pyrrolidinopentiophenone (n = 1). In patients with a known acute coronary syndrome type (n = 157), ST-segment elevation myocardial infarction was diagnosed in 53 patients (75%) and non-ST-segment elevation myocardial infarction in 18 patients (25%). Of the ST-segment elevation myocardial infarction patients, 36% were diagnosed with significant coronary stenosis or thrombus. The mortality rate for khat-associated acute coronary syndrome, with more often male and older patients with fewer cardiovascular risk factors, was higher compared to non-khat-associated acute coronary syndrome. For amfetamine, metamfetamine, and 3,4-methylenedioxymetamfetamine, mortality associated with ST--segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction was 14% and 7%, respectively. Risk factors for acute coronary syndrome were infrequently reported, and risk stratification scores were not reported.
CONCLUSION: There is evidence that amfetamine-type stimulants and cathinones are associated with the occurrence of acute coronary syndrome. Khat chewing appears to be a risk factor for acute coronary syndrome. Amfetamine, metamfetamine, 3,4-methylenedioxymetamfetamine, fenethylline, 4-fluoroamfetamine, and synthetic cathinones were also reported in relation to acute coronary syndrome. However, this evidence is limited, of low quality and with a low number of reported cases. Further prospective studies need to be conducted.
参考来源
- Gresnigt FMJ, Smits ES, den Haan C, et al. The association of amfetamines and cathinones with acute coronary syndrome - a systematic review. Clin Toxicol (Phila). 2023. PMID: 37171152. doi:10.1080/15563650.2023.2191819
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。